Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07237659 · ClinicalTrials.gov registry record · Phase 1
Phase 1a/b Tolerability of NTR-1011 in Healthy Adults and Adult Patients With SLE and RA
A Phase 1 study of SLE (Systemic Lupus) and RA - Rheumatoid Arthritis, sponsored by Neutrolis.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 48
- Enrollment target
- 1
- Study location
NCT07237659 is a Phase 1 study of SLE (Systemic Lupus) and RA - Rheumatoid Arthritis that is actively recruiting participants, run by Neutrolis. The registered enrollment target is 48 participants, above the 32-participant average among 6 other SLE (Systemic Lupus) trials with a reported enrollment target (50% higher). The trial reports 1 study location across 1 state.
The verdict
NCT07237659, a Phase 1 study of SLE (Systemic Lupus) and RA - Rheumatoid Arthritis, is actively recruiting participants, sponsored by Neutrolis.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 48 participants
- Enrollment target
- 1
- Study location
Study Summary
This phase 1a and 1b study is designed to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, immunogenicity, and preliminary efficacy of NTR-1011 in healthy adults and in adult patients with systemic lupus erythematosus and rheumatoid arthritis. The main goals of this study are to determine the safety profile of NTR-1011 across subcutaneous and intravenous dose levels, understand how the drug behaves in the body, characterize its biological activity through relevant pharmacodynamic markers, assess the potential for immune responses to treatment, and explore early signals of clinical benefit in autoimmune disease settings. This is a randomized, double blind, placebo controlled study that begins with a single ascending dose evaluation in healthy volunteers followed by a multiple dose assessment in patients. The design is intended to define the highest safe and well tolerated dose, establish a robust PK and PD baseline, and generate initial patient level evidence to support dose selection and advancement into subsequent clinical development.
Conditions Studied
Interventions
- DRUG NTR1011
Study Locations (1)
California
- California Clinical Trials Medical Group - Glendale
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 48 participants |
| Start Date | 2025-09-04 |
| Est. Completion | 2026-01-07 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07237659
The ClinicalTrials.gov registry entry for NCT07237659 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 48 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 32-participant average among 6 other SLE (Systemic Lupus) trials with a reported enrollment target (50% higher). The listed sponsor is Neutrolis, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with SLE (Systemic Lupus) appearing as the primary indexed condition, and to 1 intervention - of which NTR1011 is the first listed.
NCT07237659 reports 1 study location spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT07237659 about?
NCT07237659 is a clinical study titled "Phase 1a/b Tolerability of NTR-1011 in Healthy Adults and Adult Patients With SLE and RA". This phase 1a and 1b study is designed to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, immunogenicity, and preliminary efficacy of NTR-1011 in healthy adults and in adult patients with systemic lupus erythematosus and rheumatoid arthritis. The main goals of this study are t...
What is the current status of trial NCT07237659?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 48 participants. The study started on 2025-09-04. Estimated completion is 2026-01-07.
What conditions does trial NCT07237659 study?
This clinical trial studies the following conditions: SLE (Systemic Lupus), RA - Rheumatoid Arthritis.
What interventions are being tested in trial NCT07237659?
The interventions under investigation include: NTR1011 (DRUG).
Who is sponsoring clinical trial NCT07237659?
This trial is sponsored by Neutrolis, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07237659 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for SLE (Systemic Lupus)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Safety and Efficacy Study Evaluating CTX112 in Adult Subjects With Refractory Autoimmune Disease
RECRUITING · Phase 1
-
A Study of CLN-978, a Subcutaneously Administered CD19-directed T Cell Engager, in Subjects With Systemic Lupus Erythematosus
RECRUITING · Phase 1
-
Study Evaluating SC291 in Subjects With Severe r/r B-cell Mediated Autoimmune Diseases (GLEAM)
ACTIVE NOT RECRUITING · Phase 1
-
A Study in Participants With Mild-to-moderate Systemic Lupus Erythematosus
ACTIVE NOT RECRUITING · Phase 1
-
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 2a Study With an Open-Label Extension Evaluating the Efficacy and Safety of VENT-03 in Adult Participants With Active Cutaneous Lupus Erythematosus With or Without Systemic Lupus Erythematosus
RECRUITING · Phase 2
-
A Multi-component, Person-centered, and Yoga-based Coaching Program for Lupus Chronic Pain
ACTIVE NOT RECRUITING · NA
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.